移植后糖尿病:高血糖药物治疗管理的最新进展
本文综述实体器官移植后糖尿病(PTDM)的药物治疗管理。PTDM影响感染、移植物存活、心血管事件和死亡率;胰岛素治疗是传统选择但伴体重增加和低血糖;非胰岛素降糖药(GLP-1受体激动剂、SGLT-2抑制剂、吡格列酮)报告安全且可能提供降糖外获益,但需更多长期对照研究。
要点
- PTDM对感染、移植物存活、心血管事件和死亡率有不良影响。
- 胰岛素是传统首选药物,但与体重增加和低血糖相关。
- 非胰岛素降糖药报告安全,可能提供心肾保护等额外获益。
核心结论
- PTDM的最佳管理需要密切监测和多学科团队中内分泌科医生的早期参与。
- 随着更多长期对照研究出现,非胰岛素降糖药在PTDM管理中的作用可能增加。
研究设计与样本
- 综述,证据来源于观察性研究、随机对照试验和Meta分析。
主要发现
- PTDM对感染、器官存活、心血管事件和死亡率有不良影响。
- 胰岛素治疗是首选药物,但与体重增加和低血糖相关。
- 非胰岛素降糖药在实体器官移植患者中报告安全,SGLT-2抑制剂和GLP-1受体激动剂可能提供心肾保护,吡格列酮可能提供心脏代谢获益。
临床怎么用
- PTDM的最佳管理需要密切监测和多学科团队中内分泌科医生的早期参与。
- 非胰岛素降糖药在PTDM中的作用可能随更多长期对照研究而增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The management of solid-organ transplantation is rapidly evolving, and posttransplant diabetes mellitus (PTDM), which is increasingly common, is a barrier to transplant success, adversely impacting infection rates, allograft survival, cardiovascular disease, quality of life, and overall mortality. Currently, the management of PTDM relies primarily on intensified insulin therapy. However, emerging studies report that several noninsulin glucose-lowering agents are safe and effective in improving metabolic control and enhancing treatment adherence. More importantly, their use in PTDM can potentially transform the long-term management of these complex patients, as some glucose-lowering agents may provide benefits beyond glycemic control. For instance, glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors may offer cardiorenal protection, and pioglitazone may treat nonalcoholic fatty liver disease (NAFLD). This review will focus on the pharmacological management of PTDM and the emerging evidence for noninsulin glucose-lowering agents in this population. EVIDENCE ACQUISITION: Evidence from observational studies, randomized controlled trials, and meta-analyses. EVIDENCE SYNTHESIS: PTDM adversely affects the outcomes of infection, organ survival, cardiovascular events, and mortality. Insulin therapy has been the drug of choice but is associated with weight gain and hypoglycemia. In contrast, noninsulin agents appear safe and may provide additional benefits, such as cardiorenal protection with SGLT-2 inhibitors and GLP-1 RA, and cardiometabolic benefits with pioglitazone, in patients undergoing solid-organ transplantation. CONCLUSIONS: Optimal care of patients with PTDM requires close monitoring and the early involvement of the endocrinologist as part of a multidisciplinary team. Noninsulin glucose-lowering agents will likely play an increasing role as more long-term, controlled studies become available in this setting.
引用
- Munoz Pena JM, Cusi K. Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia. J Clin Endocrinol Metab. 2023. PMID: 37410930. doi:10.1210/clinem/dgad395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。